Polyarteritis nodosa resistant to conventional treatment in a pediatric patient

Annals of Pharmacotherapy

Volumn 41, Issue 5, 2007, Pages 885-890

  González Fernández, María Angeles ^a   García Consuegra, Julia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bosentan; Corticosteroids; Cyclophosphamide; Iloprost; Intravenous immunoglobulins; Pediatrics; Polyarteritis nodosa

Indexed keywords

AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ALLOPATHY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FINGER; HOSPITAL ADMISSION; HUMAN; PEDIATRICS; POLYARTERITIS NODOSA; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN NECROSIS; THERAPY EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ARTHRALGIA; AZATHIOPRINE; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FEVER; HUMANS; ILOPROST; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; POLYARTERITIS NODOSA; SULFONAMIDES; VASODILATOR AGENTS;

EID: 34248570682     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H637     Document Type: Article

References (25)

1. Jeannette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;187-192.
2. García-Consuegra J, Merino Muñoz R. Poliarteritis nodosa. An Pediatr 2005;62:267-70.
3. Guillevin L, Mahr A, Cohen P. [Systemic necrotising vascularitides: classification and current treatment strategies] French. Rev Med Interne 2003;24:172-82.
4. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
5. Fatalla B, Miller L, Brady S, Schaller J. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol 2005;53:724-9
6. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic poliangiitis with poor prognosis factors: a prospective trial comparing glucocorticosteroids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
7. Jayne D, Rasmussen N, Andrassy K, et al. A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
8. Taylor CT, Buring SM, Taylor KH. Treatment of Wegener's granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 1999;33:1055-9. DOI 10.1345/aph.18439.
9. Jayne D, Davies M, Fox C, Black C, Lockwood C. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137-9.
10. Finkel TS, Török TJ, Ferguson PJ. et al. Chronic parvovirus B19 infection and systemic necrotizing vasculitis: opportunistic infection or etiological agent. Lancet 1994;343:1250-8.
11. Uziel Y, Silvermen ED. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol 1998;16:187-9.
12. Wigley FM, Seibold JR, Wise RA, McClaskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
13. Zahavi J, Charach G, Schafer R, Toeg A, Zahavi M. Ischaemic necrotic toes associated with antiphospholipid syndrome and treatment with iloprost (letter). Lancet 1993;342:862.
14. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic property and therapeutical potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
15. Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology 2004;43:229-33.
16. Zulian F, Costantini C, Montesco M, Schiavon F, Zacchello F. Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost. Br J Rheumatol 1998;37:228-30.
17. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
18. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud phenomenon. Lancet 1990;336:1144-7.
19. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980;59:393-408.
20. Rubin U, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension with endothelin receptor antagonist. N Engl J Med 2002;346:896-903.
21. Korn JH, Mayes M, Matucci C, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
22. Launay D, Diot E, Pasquier E, et al. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis (9 cases)] French. Presse Med 2006;35:587-92.
23. Ramos Casals M, Brito-Zeron P, Nardi N, et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 2004;43:1454-6.
24. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS. Resolution of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 2005;142:802-3.
25. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.